Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

Summary

This is an open-label, multicenter, Phase Ib study to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) in the weekly (QW) and/or every 3 weeks (Q3W) regimens, safety, tolerability, PK, immunogenicity, PD profile and to evaluate preliminary anti-tumor activity of RO7122290 in combination with cibisatamab Q3W after pretreatment with obinutuzumab, in participants with previously treated metastatic, microsatellite-stable colorectal adenocarcinoma with high CEACAM5 expression

Timeline

Start

2021-07-14

Primary completion

2024-11-11

Completion

2024-11-11

Publications

• Melero I, Tanos T, Calvo Aller E, Qvortrup C, van Dongen M, Baraibar I, Beom SH, Thistlethwaite F, Riesco MDC, Garcia MM, Woodcock V, Kim TW, Umana P, McIntyre C, Chen L, Heichinger C, Hinton H, Saylan T, Davydov II, Guarin E, Boehnke A, Moreno V. Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial. Nat Med. 2026 Apr 20. doi: 10.1038/s41591-026-04380-z. Online ahead of print.

Drugs

Indications